Analysts Set Expectations for Personalis FY2029 Earnings

Personalis, Inc. (NASDAQ:PSNL) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for Personalis in a research note issued on Monday, January 27th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn $0.35 per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.37) per share.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.31). Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $25.71 million for the quarter, compared to the consensus estimate of $20.67 million. During the same quarter last year, the company earned ($0.51) EPS.

PSNL has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and set a $7.25 target price on shares of Personalis in a report on Wednesday, January 8th. Lake Street Capital upped their price target on shares of Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th.

Personalis Stock Down 5.1 %

Shares of NASDAQ:PSNL opened at $5.81 on Tuesday. The firm’s 50 day simple moving average is $4.87 and its 200-day simple moving average is $4.72. Personalis has a one year low of $1.12 and a one year high of $7.20.

Institutional Trading of Personalis

Several large investors have recently bought and sold shares of the business. ARK Investment Management LLC lifted its holdings in shares of Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock worth $38,120,000 after acquiring an additional 723,637 shares during the last quarter. Geode Capital Management LLC lifted its stake in Personalis by 20.0% during the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after purchasing an additional 83,068 shares in the last quarter. abrdn plc acquired a new position in Personalis during the fourth quarter worth $1,722,000. State Street Corp boosted its position in shares of Personalis by 34.5% during the third quarter. State Street Corp now owns 175,142 shares of the company’s stock worth $942,000 after buying an additional 44,900 shares during the period. Finally, Walleye Capital LLC acquired a new stake in shares of Personalis in the third quarter valued at $897,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.